Canagliflozin 100mg

DRUG4 trials

Sponsors

Janssen Research & Development, LLC, Université de Sherbrooke, National Cheng-Kung University Hospital, Taichung Veterans General Hospital

Conditions

Acute Ischemic Stroke From Large Vessel OcclusionDiabetes Mellitus, Type 2Fatty Liver DiseaseHeart FailureType2 Diabetes

Phase 3

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

CompletedNCT01381900

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2011-08-31End: 2012-11-30Updated: 2014-05-09

Phase 4

SGLT2 Inhibitor Utilization Re-perfusion Therapy

Not yet recruitingNCT06858436

Taichung Veterans General HospitalAcute Ischemic Stroke From Large Vessel Occlusion

Start: 2026-04-13End: 2027-10-31Target: 150Updated: 2026-04-03

Unknown Phase

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

WithdrawnNCT03298009

Université de SherbrookeHeart Failure, Type2 Diabetes

Start: 2018-05-01End: 2018-06-30Updated: 2024-12-13

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

CompletedNCT05764811

National Cheng-Kung University HospitalFatty Liver Disease

Start: 2020-03-06End: 2022-12-31Updated: 2023-03-13